{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041158","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.123694+00:00","generated_at":"2026-06-04T05:25:49.853115+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Praxis Precision Medicines prices $56.50/share offering, expected $215.6M net proceeds","bullets":["Offering includes 3,318,585 shares at $56.50 and 221,238 pre-funded warrants at $56.4999; underwriters exercised option for 530,973 additional shares.","Net proceeds of ~$215.6M after discounts and expenses; closing expected April 2, 2024.","Proceeds to accelerate PRAX-628 development and continue R&D for ulixacaltamide, PRAX-562, and PRAX-222.","Company believes existing cash plus net proceeds will fund operations into 2027.","Underwriters: Piper Sandler, Guggenheim Securities, and Truist Securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041158","json":"https://secwatch.observer/filing/0001104659-24-041158.json","markdown":"https://secwatch.observer/filing/0001104659-24-041158.md","text":"https://secwatch.observer/filing/0001104659-24-041158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000110465924041158/0001104659-24-041158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000110465924041158/tm247764d6_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:25:49.853115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}